CClinicalTrials.gg
CompletedNCT03480711POAGUpdated Jul 19, 2022

Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma

An interventional study of SST in group (A) and trabeculectomy with ESST in group (B) in Primary Open-angle Glaucoma, sponsored by Rehab mahmoud abdelhamid mohamed. Completed at 1 site in Egypt. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Rehab mahmoud abdelhamid mohamed · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

  • To evaluate prospectively the surgical outcome in terms of intraocular pressure control, potential advantages, disadvantages, success rate, complications and bleb morphology of this modified trabeculectomy with an extended subscleral tunnel (ESST) in comparison to the conventional subscleral trabeculectomy (SST) in management of uncontrolled primary open angle glaucoma.
  • This study will recruit 40 eyes of (40) candidate patients with primary open angle glaucoma (POAG) who are indicated for surgery.
  • The candidate patients will be recruited into 2 equal comparative groups. In group (A) 20 eyes (20 patients) who will undergo conventional (SST) with intraoperative mitomycin C (MMC) (0.03%) and group (B); 20 eyes of 20 patients will undergo trabeculectomy with an ESST also with intraoperative adjunctive MMC (0.03%).
Read the detailed description
  • Different surgical procedures were developed and the principle behind them was to establish a fistula between the anterior chamber and the subconjunctival space to permit the aqueous humour to exit the eye.
  • Subscleral trabeculectomy has remained the most commonly performed glaucoma surgery to which the newer operations are compared.Although this procedure is very effective in reducing intraocular pressure (IOP) immediately, surgical failure has often been observed over time due to fibrosis of the surgical site and resultant non-filtering bleb. -Improvement of the complication profile and the efficacy of glaucoma filtering surgery is still a major concern for glaucoma surgeons.Therefore, several modifications, combinations, and new techniques of subscleral trabeculectomy have been described.
  • In the current study, a fornix-based conjunctival flap will be fashioned in an attempt to encourage more posterior drainage. In this modified trabeculectomy technique, an additional small perpendicular strip of sclera is removed extending from the AC to 2 mm beyond the edge of the scleral flap thus creating an extended subscleral trabeculectomy facilitating aqueous passage into the posterior subconjunctival space.
02

Conditions studied

  • Primary Open-angle Glaucoma

Keywords

  • subscleral trabeculectomy
  • extended subscleral tunnel
  • mitomycinC
03

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with POAG aged from (40- 70) years who are candidate for glaucoma surgery with BCVA ≥ 3/60 to be able to perform visual field testing.
  • Non- compliant patients to the medical treatment willing for follow-up visits for at least 6 months post-operatively .

Exclusion criteria

Exclusion Criteria:

  • Congenital, traumatic, neovascular, uveitic glaucomas or cases with angle closure glaucoma (ACG) associated with shallow AC.
  • Undergoing simultaneous cataract surgery.
  • Previous vitreo-retinal surgery including vitrectomy and buckling surgery.
  • Other pre-existing ocular cicatrizing diseases.
  • Corneal abnormality that precluded reliable applanation tonometry.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group (A)

    20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml

    Procedure: SST in group (A)

  • Experimental
    group (B)

    20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)

    Procedure: trabeculectomy with ESST in group (B)

Interventions

  • ProcedureSST in group (A)

    group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml

    Also known as: subscleral trabeculectomy, conventional trabeculectomy

  • Proceduretrabeculectomy with ESST in group (B)

    group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)

    Also known as: modified trabeculectomy, extended subscleral tunnel

05

What researchers measure

Primary outcomes

  1. change from baseline intraocular pressure at first day postoperative

    mmHg

    Time frame: day one postoperatively

  2. change from baseline intraocular pressure at 4 weeks

    mmHg

    Time frame: , 4 weeks.

  3. change from baseline intraocular pressure at 6 weeks Ultrasound bimicroscopy (UBM)

    mm Hg

    Time frame: 6 weeks post-operatively.

  4. change from baseline intraocular pressure at 3 months

    mmHg

    Time frame: 3 months postoperatively

  5. change from baseline intraocular pressure at 6 months

    mmHg

    Time frame: 6 months postoperatively

Secondary outcomes

  1. change from baseline best corrected visual acuity (BCVA) at 6 months

    logarithm of minimal angle of resolution (log MAR)

    Time frame: at the end of 6 months

  2. extent of filtering bleb area by ultrasound of bio-microscopy (UBM)

    width, depth and height of filtering bleb area in millimeter

    Time frame: 6 weeks postoperatively

06

Study locations

1 site
  • Faculty of medicind
    Cairo, Egypt
07

References and documents

Publications

  • El Sayyad F, Belmekki M, Helal M, Khalil M, El-Hamzawey H, Hisham M. Simultaneous subconjunctival and subscleral mitomycin-C application in trabeculectomy. Ophthalmology. 2000 Feb;107(2):298-301; discussion 302. doi: 10.1016/s0161-6420(99)00097-4. PubMed 10690829 ↗
  • Nuijts RM, Vernimmen RC, Webers CA. Mitomycin C primary trabeculectomy in primary glaucoma of white patients. J Glaucoma. 1997 Oct;6(5):293-7. PubMed 9327347 ↗

Individual participant data

Plan to share: Undecided — study protocol Statistical analysis plan within 6 months after completing the study

08

Registry details

Key details

Study ID
NCT03480711
Lead sponsor
Rehab mahmoud abdelhamid mohamed
Collaborators
Cairo University
Responsible party
Rehab mahmoud abdelhamid mohamed (assistant lecturer of ophthalmology,ophthalmology department, medical school, Cairo University) — Sponsor-investigator
First posted
Mar 29, 2018
Start date
Jul 10, 2018
Primary completion
Feb 28, 2019
Completion
Mar 2, 2019
Last update
Jul 19, 2022

Study contacts

Riham S Allam, MD, FRCS GL
principal investigator · Associate Professor of Ophthalmology , Cairo university
Karim A Raafat, MD
principal investigator · Professor of Ophthalmology , Cairo university
Rehab M Mohamed, MD
principal investigator · lecturer of Ophthalmology , Cairo university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion